BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate ...

This was the stock's second consecutive day of losses.

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing ...

After dropping by 15.74% to close at $1,707.94 yesterday, the stock could continue to pull back today. Shares fell after ...

The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.